Ocugen (OCGN) Competitors

Ocugen (NASDAQ:OCGN) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.

Do institutionals and insiders believe in OCGN or ZYME?

10.3% of Ocugen shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 4.3% of Ocugen shares are held by insiders. Comparatively, 1.9% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer OCGN or ZYME?

Zymeworks received 181 more outperform votes than Ocugen when rated by MarketBeat users. However, 71.07% of users gave Ocugen an outperform vote while only 67.74% of users gave Zymeworks an outperform vote.

Company	Underperform	Outperform
Ocugen	Outperform Votes 113 71.07%	Underperform Votes 46 28.93%
Zymeworks	Outperform Votes 294 67.74%	Underperform Votes 140 32.26%

Which has more volatility & risk, OCGN or ZYME?

Ocugen has a beta of 3.78, suggesting that its share price is 278% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Is OCGN or ZYME more profitable?

Zymeworks has a net margin of -182.75% compared to Ocugen's net margin of -532.51%. Zymeworks' return on equity of -23.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-532.51%	-154.75%	-90.79%
Zymeworks	-182.75%	-23.00%	-18.04%

Does the media favor OCGN or ZYME?

In the previous week, Zymeworks had 8 more articles in the media than Ocugen. MarketBeat recorded 11 mentions for Zymeworks and 3 mentions for Ocugen. Zymeworks' average media sentiment score of 1.12 beat Ocugen's score of 0.37 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer OCGN or ZYME?

Ocugen currently has a consensus price target of $6.33, indicating a potential upside of 806.32%. Zymeworks has a consensus price target of $21.00, indicating a potential upside of 91.96%. Given Ocugen's stronger consensus rating and higher possible upside, research analysts plainly believe Ocugen is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zymeworks	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Which has better earnings and valuation, OCGN or ZYME?

Ocugen has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.06M	50.32	-$63.08M	-$0.19	-3.68
Zymeworks	$76.30M	9.98	-$118.67M	-$1.61	-6.80

Summary

Zymeworks beats Ocugen on 10 of the 19 factors compared between the two stocks.